Liminatus Pharma Warrants
LIMNW
21 hedge funds and large institutions have $72.6K invested in Liminatus Pharma Warrants in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.
11.29% less ownership
Funds ownership: 31.82% → 20.53% (-11%)
13% less funds holding
Funds holding: 24 → 21 (-3)
24% less capital invested
Capital invested by funds: $95K → $72.6K (-$22.4K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$19 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
-$51.5K |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$1.5K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$837 |
| 4 |
GS
GTS Securities
New York
|
-$555 |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$434 |
LIMNW Hedge Fund Activity: Q1 2026 in Review
21 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Liminatus Pharma Warrants (LIMNW) for Q1 2026, worth a combined $72.6K — down 24% from $95K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of LIMNW and 0 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 1 added.
The largest buyer was UBS Group, adding an estimated $19. The largest seller was Clear Street, cutting an estimated $51.5K.
- 21 institutional investors held Liminatus Pharma Warrants (LIMNW) as of Q1 2026, down from 24 in Q4 2025.
- Funds reported $72.6K of Liminatus Pharma Warrants stock for Q1 2026, down 24% quarter-over-quarter.
- 0 funds opened new Liminatus Pharma Warrants positions in Q1 2026 and 3 closed out, a net change of -3 holders.
- The largest Liminatus Pharma Warrants buyer in Q1 2026 was UBS Group, an estimated $19 added.
- The largest Liminatus Pharma Warrants seller in Q1 2026 was Clear Street, an estimated $51.5K sold.
Based on aggregated 13F filings for Q1 2026.